Genpharmasec Limited

ADIRASA

INE861N01036

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:56 01/07/2024 BST			5-day change	1st Jan Change
2.16 ^INR	+4.85%		+11.34%	-53.75%

05-24	Genpharmasec Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-24	Genpharmasec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Genpharmasec Limited Appoints Heta Shah as Company Secretary and Compliance Officer, with Effect from October 7, 2022

October 07, 2022 at 08:39 am

Genpharmasec Limited appointed Mrs. Heta Shah (having Membership No.: A69749), as Company Secretary & Compliance Officer from 7th October 2022.

Latest news about Genpharmasec Limited

Genpharmasec Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-24	CI
Genpharmasec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-24	CI
Genpharmasec Limited Announces Appointment of Hardik Makwana as Company Secretary & Compliance Officer	03-27	CI
Genpharmasec Limited Announces Resignation of Heta Shah as Company Secretary / Compliance Officer	03-20	CI
Genpharmasec Limited Announces Resignation of Ulhas Narayan Deosthale from the Post of Executive Director	03-12	CI
Genpharmasec Limited completed the acquisition of an unknown stake in Derren Healthcare Private Limited from the existing shareholder.	03-10	CI
Genpharmasec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Genpharmasec Forms Subsidiary for Molecular Testing Services	01-29	MT
Genpharmasec Limited Forms New Wholly Owned Subsidiary Company Namely Clinigenome India Private Limited	01-29	CI
Genpharmasec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Genpharmasec to Acquire 70% Stake in Derren Healthcare for INR126.4 Million	20/09/23	MT
Genpharmasec Limited signed a share purchase agreement to acquire an unknown stake in Derren Healthcare Private Limited from the existing shareholder for approximately INR 130 million.	18/09/23	CI
Genpharmasec Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/08/23	CI
Genpharmasec Sets Up Middle East Unit	14/07/23	MT
Genpharmasec Limited Incorporates Foreign Subsidiary Namely Genpharmasec Middle East DMCC	14/07/23	CI
Genpharmasec Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	26/05/23	CI
Genpharmasec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/02/23	CI
Genpharmasec Limited Announces Board Changes	01/11/22	CI
Genpharmasec Limited Announces CFO Changes	01/11/22	CI
Genpharmasec Limited Appoints Heta Shah as Company Secretary and Compliance Officer, with Effect from October 7, 2022	07/10/22	CI
Genpharmasec Limited Announces Resignation of Amisha Mitesh Dani as Independent Director	06/10/22	CI
Genpharmasec Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/08/22	CI
Genpharmasec Limited Announces Executive Appointments	04/07/22	CI
Genpharmasec Limited Announces Director Resignations with Effect from June 21, 2022	21/06/22	CI
Genpharmasec Limited Announces Resignation of Independent Directors	18/06/22	CI

Genpharmasec Ltd is an India-based company, which is engaged in the distribution of the lucrative medical and diagnostics device segment. It is engaged in providing technology-based medical and diagnostics devices. The Company operates through two segments: Distribution of Diagnostic Equipmentâs and Investment and trading in Securities. The Company holds rights for distribution of equipments, such as i-STAT Analyzers and its Cartridges manufactured by Abbott Point of Care, USA all over India. The Company also holds distribution rights of Sphingotec Biomarkers and Joinstar System through Rivaara Labs Private Limited.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENPHARMASEC LIMITED	-53.75%	13.68M
ELI LILLY AND COMPANY	+56.86%	815B
NOVO NORDISK A/S	+43.90%	641B
JOHNSON & JOHNSON	-6.57%	352B
MERCK & CO., INC.	+17.32%	314B
ABBVIE INC.	+9.94%	303B
ASTRAZENECA PLC	+16.08%	242B
ROCHE HOLDING AG	+2.29%	224B
NOVARTIS AG	+13.96%	218B
AMGEN INC.	+7.98%	168B